Evolution of statin prescribing 1994–2001: a case of agism but not of sexism?

Objective: To study trends in the use of lipid lowering drugs in the UK, and to assess which patient factors influence prescribing. Methods: Routinely collected computerised medical data were analysed from 142 general practices across England and Wales that provide data for the Doctors’ Independent...

Full description

Saved in:
Bibliographic Details
Published inHeart (British Cardiac Society) Vol. 89; no. 4; pp. 417 - 421
Main Authors DeWilde, S, Carey, I M, Bremner, S A, Richards, N, Hilton, S R, Cook, D G
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd and British Cardiovascular Society 01.04.2003
BMJ
BMJ Publishing Group Ltd
BMJ Publishing Group LTD
Copyright 2003 by Heart
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objective: To study trends in the use of lipid lowering drugs in the UK, and to assess which patient factors influence prescribing. Methods: Routinely collected computerised medical data were analysed from 142 general practices across England and Wales that provide data for the Doctors’ Independent Network database. Subjects included were people aged 35 years or more with treated ischaemic heart disease, averaging annually over 30 000. The temporal trend from 1994 to 2001 in prescription of lipid lowering drugs and daily statin dose and the odds ratios (ORs) for receiving a statin prescription in 1998 were examined. Results: Lipid lowering drug prescribing increased greatly over time, entirely because of statins, so that in 2001 56.3% of men and 41.1% of women with ischaemic heart disease received lipid lowering drugs. However, 33% of these patients were on a < 20 mg simvastatin daily equivalent. In 1998 the OR for receiving a statin fell from 1 at age 55–64 to 0.64 at 65–74 and 0.16 at 75–84 years. The age effect was similar in those without major comorbidity. Revascularised patients were much more likely to receive a statin than those with angina (OR 3.92, 95% confidence interval (CI) 3.57 to 4.31). Men were more likely to receive a statin than women (OR 1.62, 95% CI 1.54 to 1.71) but this difference disappeared after adjustment for age and severity of disease (OR 1.06). Geographical region had little effect but there was a very weak socioeconomic gradient. Conclusions: Although prescribing has increased, many patients who may benefit from lipid lowering drugs either do not receive it or are undertreated, possibly because of lack of awareness of the relative potency of the different statins. Patients with angina and the elderly are less likely to receive treatment that may prevent a coronary event.
AbstractList Objective: To study trends in the use of lipid lowering drugs in the UK, and to assess which patient factors influence prescribing. Methods: Routinely collected computerised medical data were analysed from 142 general practices across England and Wales that provide data for the Doctors’ Independent Network database. Subjects included were people aged 35 years or more with treated ischaemic heart disease, averaging annually over 30 000. The temporal trend from 1994 to 2001 in prescription of lipid lowering drugs and daily statin dose and the odds ratios (ORs) for receiving a statin prescription in 1998 were examined. Results: Lipid lowering drug prescribing increased greatly over time, entirely because of statins, so that in 2001 56.3% of men and 41.1% of women with ischaemic heart disease received lipid lowering drugs. However, 33% of these patients were on a < 20 mg simvastatin daily equivalent. In 1998 the OR for receiving a statin fell from 1 at age 55–64 to 0.64 at 65–74 and 0.16 at 75–84 years. The age effect was similar in those without major comorbidity. Revascularised patients were much more likely to receive a statin than those with angina (OR 3.92, 95% confidence interval (CI) 3.57 to 4.31). Men were more likely to receive a statin than women (OR 1.62, 95% CI 1.54 to 1.71) but this difference disappeared after adjustment for age and severity of disease (OR 1.06). Geographical region had little effect but there was a very weak socioeconomic gradient. Conclusions: Although prescribing has increased, many patients who may benefit from lipid lowering drugs either do not receive it or are undertreated, possibly because of lack of awareness of the relative potency of the different statins. Patients with angina and the elderly are less likely to receive treatment that may prevent a coronary event.
Objective: To study trends in the use of lipid lowering drugs in the UK, and to assess which patient factors influence prescribing. Methods: Routinely collected computerised medical data were analysed from 142 general practices across England and Wales that provide data for the Doctors' Independent Network database. Subjects included were people aged 35 years or more with treated ischaemic heart disease, averaging annually over 30 000. The temporal trend from 1994 to 2001 in prescription of lipid lowering drugs and daily statin dose and the odds ratios (ORs) for receiving a statin prescription in 1998 were examined. Results: Lipid lowering drug prescribing increased greatly over time, entirely because of statins, so that in 2001 56.3% of men and 41.1% of women with ischaemic heart disease received lipid lowering drugs. However, 33% of these patients were on a < 20 mg simvastatin daily equivalent. In 1998 the OR for receiving a statin fell from 1 at age 55-64 to 0.64 at 65-74 and 0.16 at 75-84 years. The age effect was similar in those without major comorbidity. Revascularised patients were much more likely to receive a statin than those with angina (OR 3.92, 95% confidence interval (CI) 3.57 to 4.31). Men were more likely to receive a statin than women (OR 1.62, 95% CI 1.54 to 1.71) but this difference disappeared after adjustment for age and severity of disease (OR 1.06). Geographical region had little effect but there was a very weak socioeconomic gradient. Conclusions: Although prescribing has increased, many patients who may benefit from lipid lowering drugs either do not receive it or are undertreated, possibly because of lack of awareness of the relative potency of the different statins. Patients with angina and the elderly are less likely to receive treatment that may prevent a coronary event.
OBJECTIVETo study trends in the use of lipid lowering drugs in the UK, and to assess which patient factors influence prescribing.METHODSRoutinely collected computerised medical data were analysed from 142 general practices across England and Wales that provide data for the Doctors' Independent Network database. Subjects included were people aged 35 years or more with treated ischaemic heart disease, averaging annually over 30,000. The temporal trend from 1994 to 2001 in prescription of lipid lowering drugs and daily statin dose and the odds ratios (ORs) for receiving a statin prescription in 1998 were examined.RESULTSLipid lowering drug prescribing increased greatly over time, entirely because of statins, so that in 2001 56.3% of men and 41.1% of women with ischaemic heart disease received lipid lowering drugs. However, 33% of these patients were on a < 20 mg simvastatin daily equivalent. In 1998 the OR for receiving a statin fell from 1 at age 55-64 to 0.64 at 65-74 and 0.16 at 75-84 years. The age effect was similar in those without major comorbidity. Revascularised patients were much more likely to receive a statin than those with angina (OR 3.92, 95% confidence interval (CI) 3.57 to 4.31). Men were more likely to receive a statin than women (OR 1.62, 95% CI 1.54 to 1.71) but this difference disappeared after adjustment for age and severity of disease (OR 1.06). Geographical region had little effect but there was a very weak socioeconomic gradient.CONCLUSIONSAlthough prescribing has increased, many patients who may benefit from lipid lowering drugs either do not receive it or are undertreated, possibly because of lack of awareness of the relative potency of the different statins. Patients with angina and the elderly are less likely to receive treatment that may prevent a coronary event.
To study trends in the use of lipid lowering drugs in the UK, and to assess which patient factors influence prescribing. Routinely collected computerised medical data were analysed from 142 general practices across England and Wales that provide data for the Doctors' Independent Network database. Subjects included were people aged 35 years or more with treated ischaemic heart disease, averaging annually over 30,000. The temporal trend from 1994 to 2001 in prescription of lipid lowering drugs and daily statin dose and the odds ratios (ORs) for receiving a statin prescription in 1998 were examined. Lipid lowering drug prescribing increased greatly over time, entirely because of statins, so that in 2001 56.3% of men and 41.1% of women with ischaemic heart disease received lipid lowering drugs. However, 33% of these patients were on a < 20 mg simvastatin daily equivalent. In 1998 the OR for receiving a statin fell from 1 at age 55-64 to 0.64 at 65-74 and 0.16 at 75-84 years. The age effect was similar in those without major comorbidity. Revascularised patients were much more likely to receive a statin than those with angina (OR 3.92, 95% confidence interval (CI) 3.57 to 4.31). Men were more likely to receive a statin than women (OR 1.62, 95% CI 1.54 to 1.71) but this difference disappeared after adjustment for age and severity of disease (OR 1.06). Geographical region had little effect but there was a very weak socioeconomic gradient. Although prescribing has increased, many patients who may benefit from lipid lowering drugs either do not receive it or are undertreated, possibly because of lack of awareness of the relative potency of the different statins. Patients with angina and the elderly are less likely to receive treatment that may prevent a coronary event.
Audience Professional
Author Bremner, S A
Carey, I M
Richards, N
DeWilde, S
Hilton, S R
Cook, D G
AuthorAffiliation 3 CompuFile Ltd, Woking, Surrey, UK
2 Department of Public Health Sciences, St George’s Hospital Medical School, London, UK
1 Department of General Practice & Primary Care, St George’s Hospital Medical School, London, UK
AuthorAffiliation_xml – name: 1 Department of General Practice & Primary Care, St George’s Hospital Medical School, London, UK
– name: 3 CompuFile Ltd, Woking, Surrey, UK
– name: 2 Department of Public Health Sciences, St George’s Hospital Medical School, London, UK
Author_xml – sequence: 1
  givenname: S
  surname: DeWilde
  fullname: DeWilde, S
  organization: CompuFile Ltd, Woking, Surrey, UK
– sequence: 2
  givenname: I M
  surname: Carey
  fullname: Carey, I M
  organization: CompuFile Ltd, Woking, Surrey, UK
– sequence: 3
  givenname: S A
  surname: Bremner
  fullname: Bremner, S A
  organization: CompuFile Ltd, Woking, Surrey, UK
– sequence: 4
  givenname: N
  surname: Richards
  fullname: Richards, N
  organization: CompuFile Ltd, Woking, Surrey, UK
– sequence: 5
  givenname: S R
  surname: Hilton
  fullname: Hilton, S R
  organization: CompuFile Ltd, Woking, Surrey, UK
– sequence: 6
  givenname: D G
  surname: Cook
  fullname: Cook, D G
  organization: CompuFile Ltd, Woking, Surrey, UK
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14612451$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/12639870$$D View this record in MEDLINE/PubMed
BookMark eNptktuKFDEQhhtZcQ9666U0ioJgjzl1Dl4oy7AeYHFBx8NdSGeqezN2J2One1nvfAff0CcxszPurDKEkFD11V9JVR1mez54yLL7GE0wpvz5OZh-mEg1YROGxa3sADMuC4Lw1710p2VZcETFfnYY4wIhxJTkd7J9TDhVUqCD7OzkIrTj4ILPQ53HwQzO58seou1d5XyTY6XY75-_CEL4RW5yayKsSNO42OXVOOQ-DFehcJksr-5mt2vTRri3OY-yT69PZtO3xenZm3fT49Oi4lgORUmE5MjKuQXCjQWMeIWkZKwG4MISYEgSQwSIcg68tFVluKEln9e4rAW19Ch7udZdjlUHScYPvWn1sned6X_oYJz-1-PduW7ChcaCK1LSJPBkI9CH7yPEQXcuWmhb4yGMUQuKEUMEJ_DRf-AijL1Pn0taEgmVNkrUwzXVmBa083VIWe1KUh8rJUqiOEnQsx1QAx7SC1Nfa5fMN_FiB57WHDpnd_EPbtbkuhh_u52AxxvARGvaujfeurjlGMeElXib2MUBLq_9pv-muaCi1O8_T_WUfkB49nGmvyT-6ZqvusVWDenVhOqrCdVSaabThNI_yGrVuw
CitedBy_id crossref_primary_10_1016_j_healthpol_2012_08_008
crossref_primary_10_1111_j_1464_5491_2004_01301_x
crossref_primary_10_1016_j_amjmed_2008_10_041
crossref_primary_10_1016_S0140_6736_03_13601_X
crossref_primary_10_1111_j_1464_5491_2004_01389_x
crossref_primary_10_1093_ageing_afm007
crossref_primary_10_1111_dme_12409
crossref_primary_10_1111_j_1365_2125_2004_02228_x
crossref_primary_10_1177_1403494810364558
crossref_primary_10_1007_s00228_007_0459_1
crossref_primary_10_1111_j_1076_7460_2003_02687_x
crossref_primary_10_1016_j_clinthera_2006_04_012
crossref_primary_10_1111_j_1467_9566_2007_01025_x
crossref_primary_10_3109_13814780509178241
crossref_primary_10_1016_j_ijcard_2004_09_015
crossref_primary_10_1111_jep_12462
crossref_primary_10_1586_14737167_5_2_113
crossref_primary_10_1186_1471_2296_6_13
crossref_primary_10_1089_jwh_2007_0383
crossref_primary_10_1186_s12872_018_0941_y
crossref_primary_10_1093_eurpub_ckm005
crossref_primary_10_1007_s00228_012_1454_8
crossref_primary_10_1016_j_jvs_2008_04_073
crossref_primary_10_1016_j_precon_2006_05_002
crossref_primary_10_1186_1472_6963_9_198
crossref_primary_10_1186_1471_2458_10_632
crossref_primary_10_1080_00325481_2020_1755146
crossref_primary_10_1136_bmjopen_2017_018524
crossref_primary_10_1161_CIRCULATIONAHA_113_004122
crossref_primary_10_1016_j_clinthera_2005_09_012
crossref_primary_10_1136_bmjopen_2018_023085
crossref_primary_10_1016_j_jclinepi_2005_01_009
crossref_primary_10_1177_1074248408328927
crossref_primary_10_1136_bmjopen_2015_008678
crossref_primary_10_1186_1472_6963_8_104
crossref_primary_10_1007_BF03169170
crossref_primary_10_1111_j_1365_2125_2005_02494_x
crossref_primary_10_2165_11312110_000000000_00000
crossref_primary_10_2165_00019053_200422080_00004
crossref_primary_10_1002_pds_1859
crossref_primary_10_1016_j_jacl_2018_10_002
crossref_primary_10_1016_j_socscimed_2005_05_028
crossref_primary_10_1016_j_ahj_2007_02_002
crossref_primary_10_1185_030079906X112688
crossref_primary_10_1111_j_1365_2125_2004_02152_x
crossref_primary_10_1016_j_amjopharm_2011_09_004
crossref_primary_10_1111_j_1368_5031_2004_00300_x
crossref_primary_10_1097_MAJ_0b013e3181e15da8
crossref_primary_10_1211_096176708784658288
crossref_primary_10_1002_pds_1172
crossref_primary_10_1007_s00228_012_1328_0
crossref_primary_10_3399_bjgp19X702701
crossref_primary_10_1177_003693300505000204
crossref_primary_10_1186_1472_6963_7_142
crossref_primary_10_1212_01_WNL_0000160114_42643_31
crossref_primary_10_1097_01_mol_0000137230_77148_ee
crossref_primary_10_1016_S0168_8278_03_00464_1
crossref_primary_10_1177_1460458218813640
crossref_primary_10_1093_pubmed_fdl052
crossref_primary_10_1111_1753_0407_12013
crossref_primary_10_3399_bjgp08X279670
crossref_primary_10_1586_14737167_7_1_31
crossref_primary_10_1136_bmjopen_2014_007299
crossref_primary_10_1161_CIRCULATIONAHA_108_846931
crossref_primary_10_1136_bmjopen_2014_007207
crossref_primary_10_1136_bmjopen_2016_014150
crossref_primary_10_1161_CIRCOUTCOMES_111_000058
crossref_primary_10_2146_ajhp050517
crossref_primary_10_1007_s11606_010_1473_z
crossref_primary_10_1016_j_ijmedinf_2004_02_002
crossref_primary_10_1093_eurheartj_eht368
crossref_primary_10_1016_j_puhe_2006_03_010
crossref_primary_10_1186_1471_2458_14_544
crossref_primary_10_1177_2042098611428486
crossref_primary_10_1016_j_numecd_2010_09_010
crossref_primary_10_1016_j_amjcard_2007_12_020
crossref_primary_10_2165_00002018_200629050_00005
crossref_primary_10_1080_13698575_2019_1667964
crossref_primary_10_1016_S0140_6736_03_14216_X
crossref_primary_10_12968_hmed_2006_67_12_22433
crossref_primary_10_1002_pds_2195
crossref_primary_10_1111_jgs_13953
crossref_primary_10_1111_j_1365_2796_2004_01315_x
crossref_primary_10_2337_dc06_0872
crossref_primary_10_3399_bjgp08X376195
crossref_primary_10_1097_HJR_0b013e3283316ce8
crossref_primary_10_1186_1471_2296_4_14
crossref_primary_10_1016_j_clinthera_2007_04_009
crossref_primary_10_1258_shorts_2011_011027
crossref_primary_10_1016_j_pcd_2014_08_001
crossref_primary_10_1097_01_mol_0000137218_37245_2e
crossref_primary_10_1016_S0755_4982_06_74768_6
crossref_primary_10_1161_CIRCULATIONAHA_106_678300
crossref_primary_10_1016_j_therap_2019_01_004
crossref_primary_10_1016_j_archger_2011_06_025
crossref_primary_10_1111_j_1742_1241_2005_00365_x
crossref_primary_10_1016_j_ijcard_2005_06_039
crossref_primary_10_1016_j_jvs_2008_04_057
crossref_primary_10_1111_j_1365_2125_2004_02256_x
ContentType Journal Article
Copyright Copyright 2003 by Heart
2003 INIST-CNRS
COPYRIGHT 2003 BMJ Publishing Group Ltd.
Copyright: 2003 Copyright 2003 by Heart
Copyright © Copyright 2003 by Heart 2003
Copyright_xml – notice: Copyright 2003 by Heart
– notice: 2003 INIST-CNRS
– notice: COPYRIGHT 2003 BMJ Publishing Group Ltd.
– notice: Copyright: 2003 Copyright 2003 by Heart
– notice: Copyright © Copyright 2003 by Heart 2003
DBID BSCLL
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
88I
8AF
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
BTHHO
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
M0S
M1P
M2P
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.1136/heart.89.4.417
DatabaseName Istex
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
STEM Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
BMJ Journals
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Science Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
ProQuest Central Student
MEDLINE - Academic
MEDLINE


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Statistics
EISSN 1468-201X
EndPage 421
ExternalDocumentID 4021463651
A99752962
12639870
14612451
ark_67375_NVC_C3R01TST_W
ttp://heart.bmj.com/content/89/4/417.full
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations England
Wales
United Kingdom
GeographicLocations_xml – name: Wales
– name: England
– name: United Kingdom
GrantInformation_xml – fundername: Wellcome Trust
GroupedDBID ---
.55
.VT
0R~
29I
2WC
354
39C
3O-
3V.
4.4
40O
53G
5GY
5RE
7X7
7~S
88E
88I
8AF
8FI
8FJ
8R4
8R5
AAFWJ
AAHLL
AAKAS
AAOJX
AAWJN
AAWTL
AAYEP
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABUWG
ABVAJ
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACOFX
ACTZY
ADBBV
ADCEG
ADUGQ
ADZCM
AEKJL
AENEX
AFFNX
AFKRA
AFWFF
AHMBA
AHNKE
AHQMW
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZFZN
AZQEC
BAWUL
BCR
BENPR
BLC
BLJBA
BOMFT
BPHCQ
BTHHO
BVXVI
C1A
CAG
CCPQU
COF
CXRWF
DIK
DU5
DWQXO
E3Z
EBS
EJD
EX3
F5P
FEDTE
FYUFA
GNUQQ
GX1
H13
HAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
IAO
IEA
IHR
INH
INR
IOF
ITC
J5H
L7B
M1P
M2P
N4W
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PCD
PEA
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
TEORI
TR2
UKHRP
UYXKK
V24
VM9
WH7
WOQ
WOW
X7M
YFH
YQY
ZGI
ZXP
BSCLL
08R
8RD
AAUGY
ABPTK
BHJZB
BJGMD
IQODW
ZA5
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
K9.
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-b618t-527860c8dce26ace106b08844fee67c2e4082a27e75de65cbba6a356df15f73c3
IEDL.DBID RPM
ISSN 1355-6037
IngestDate Tue Sep 17 21:09:48 EDT 2024
Sat Aug 17 05:34:24 EDT 2024
Thu Oct 10 17:42:07 EDT 2024
Wed Feb 28 18:08:07 EST 2024
Wed Nov 13 05:21:16 EST 2024
Tue Nov 12 23:42:11 EST 2024
Sat Nov 02 12:23:41 EDT 2024
Sun Oct 22 16:02:14 EDT 2023
Wed Oct 30 09:15:13 EDT 2024
Wed Aug 21 02:05:37 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Human
Prognosis
Enzyme
Hydroxymethylglutaryl-CoA synthase
Sex
Enzyme inhibitor
Cardiovascular disease
Metabolic diseases
Lipids
Hyperlipoproteinemia
Lyases
Coronary heart disease
Oxo-acid-lyases
Carbon-carbon lyases
Chemotherapy
Hypercholesterolemia
Treatment
Medical prescription
Risk factor
Dyslipemia
Age
Antilipemic agent
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b618t-527860c8dce26ace106b08844fee67c2e4082a27e75de65cbba6a356df15f73c3
Notes href:heartjnl-89-417.pdf
PMID:12639870
ark:/67375/NVC-C3R01TST-W
Correspondence to:
 Professor D Cook, Department of Public Health Sciences, St George’s Hospital Medical School, Cranmer Terrace, London SW17 ORE, UK;
 d.cook@sghms.ac.uk
istex:4F34E4A0A967D5C684F3D9680C3CED0B1773F21E
local:0890417
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Also the Department of Public Health Sciences
Conflicts of interest: NR is a director of CompuFile Ltd, which markets data to pharmaceutical companies.
Correspondence to: …Professor D Cook, Department of Public Health Sciences, St George’s Hospital Medical School, Cranmer Terrace, London SW17 ORE, UK; …d.cook@sghms.ac.uk
OpenAccessLink https://heart.bmj.com/content/heartjnl/89/4/417.full.pdf
PMID 12639870
PQID 1780798070
PQPubID 2041068
PageCount 5
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_1769253
proquest_miscellaneous_73104021
proquest_journals_1780798070
gale_infotracmisc_A99752962
gale_infotracgeneralonefile_A99752962
gale_infotracacademiconefile_A99752962
pubmed_primary_12639870
pascalfrancis_primary_14612451
istex_primary_ark_67375_NVC_C3R01TST_W
bmj_primary_10_1136_heart_89_4_417
PublicationCentury 2000
PublicationDate 2003-04-01
PublicationDateYYYYMMDD 2003-04-01
PublicationDate_xml – month: 04
  year: 2003
  text: 2003-04-01
  day: 01
PublicationDecade 2000
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Heart (British Cardiac Society)
PublicationTitleAlternate Heart
PublicationYear 2003
Publisher BMJ Publishing Group Ltd and British Cardiovascular Society
BMJ
BMJ Publishing Group Ltd
BMJ Publishing Group LTD
Copyright 2003 by Heart
Publisher_xml – name: BMJ Publishing Group Ltd and British Cardiovascular Society
– name: BMJ
– name: BMJ Publishing Group Ltd
– name: BMJ Publishing Group LTD
– name: Copyright 2003 by Heart
SSID ssj0004986
Score 2.161193
Snippet Objective: To study trends in the use of lipid lowering drugs in the UK, and to assess which patient factors influence prescribing. Methods: Routinely...
To study trends in the use of lipid lowering drugs in the UK, and to assess which patient factors influence prescribing. Routinely collected computerised...
OBJECTIVETo study trends in the use of lipid lowering drugs in the UK, and to assess which patient factors influence prescribing.METHODSRoutinely collected...
Objective: To study trends in the use of lipid lowering drugs in the UK, and to assess which patient factors influence prescribing. Methods: Routinely...
SourceID pubmedcentral
proquest
gale
pubmed
pascalfrancis
istex
bmj
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 417
SubjectTerms a classification of residential neighbourhoods
ACORN
Adult
Age
Age Factors
Aged
Aged, 80 and over
Biological and medical sciences
Cardiac patients
Cardiovascular Medicine
Care and treatment
CHD
coronary heart disease
DIN
Doctors’ Independent Network
Drug dosages
Drug therapy
Drug use
England
Family Practice - trends
Female
General and cellular metabolism. Vitamins
General Practice Research Database
GPRD
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hyperlipidemia
IHD
ischaemic heart disease
key health statistics
KHS
lipid lowering drugs
Lipids
Male
Medical sciences
Mens health
Middle Aged
myocardial infarction
Myocardial Ischemia - prevention & control
patient factors
Patients
Pharmacology. Drug treatments
Practice Patterns, Physicians' - trends
Prejudice
prescribing patterns
Prevention
Sex Factors
Statins
Statistics
Studies
Time Factors
Trends
Wales
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELbYJiFeEL_JNkaEYG_pktixHV6mqdo0IXUP0EHfLNu1u4KabEuK-PO5c7J2RRMPffIldS535-_iz3eEfCy9MVL6NEGKecJobsGlAMgVznAP-NoXGk8jjy74-SX7Mikm_Qe3pqdV3sXEEKintcVv5EeZkKko4ZceX98k2DUKd1f7FhpbZCfLU46ULjER63ORZej0mMGamvCUir5oY0b5EbaLbgeyHLABw2ZlW2bxcxWVd1DDf5AmqRvQlO9aXDyEQf-lUt5bm86ekac9qIxPOit4Th656gV5POq3zV-S0env3sLi2sd4hmhexciAhZABmfEsDqV7kff0OdaxhYUN5fRs3ixis2zjqm7DhVg2c3H8ilyenY6H50nfRyExPJMt5JpC8tRKmGTOtXWQBRoILox557iwucOm0zoXThRTxwtrjOaaFnzqs8ILaulrsl3VlXtLYqOlK41OqWeSUdqVBwOQJqz3U8i9IvIBFKmuu0oZKmQYlKugbSVLxRRoOyKHqGeFLgRKs7o_CQB_gcWo1ElZCtwOziPyaUNw1lXifkBub0MOPMTeHz0M73M1K337C-lsolAX34dqSL-m2fjbWP2IyMHGC18_BgMcyAp4uv07C1C9qzdqbZgReb8axikgfa1y9bJRAkA0JOpwgzeduaxvnQNElHit2DCklQCW_94cqeZXoQx4JniZF3T3_5PaI08C_zCQjfbJdnu7dO8AR7XmIDjLX5uMGSo
  priority: 102
  providerName: ProQuest
Title Evolution of statin prescribing 1994–2001: a case of agism but not of sexism?
URI http://dx.doi.org/10.1136/heart.89.4.417
https://api.istex.fr/ark:/67375/NVC-C3R01TST-W/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/12639870
https://www.proquest.com/docview/1780798070
https://search.proquest.com/docview/73104021
https://pubmed.ncbi.nlm.nih.gov/PMC1769253
Volume 89
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtNAEF41rYS4IP5rWoKFoLcktvfXXFCJUlVICVVJIbfV7mY3BLBTNQ7iyDvwhjwJs2snbVBPHHzasb0ez-zOaL_5BqFXudNaCJd0PMS8Q3BmwKUgkKNWMwfxtaPKVyMPR-z0gryf0MkOoutamADaN3reLb8X3XL-JWArLwvTW-PEemfDfspZnlHca6EWGOg6RV8XQ-ahvWMKG2mHJZg3TI0pZj3fI7rqirxLuiQN7fcy2KCFb1Tc0sXXzaq85zX808Mk1RI05eoWF7fFoP9CKW_sTSf30b0mqIyP68k_QDu2fIjuDJtj80fow-BHY2HxwsW-hmhexh4BC0sGZMaz2FP3_vn12yOf3sQqNrC1eUk1my-LWK-quFxU4VZPnFm8fYwuTgbj_mmn6aTQ0SwVFWSbXLDECJhmxpSxkAdqWF4IcdYybjLr206rjFtOp5ZRo7ViClM2dSl1HBv8BO2Wi9Luo1grYXOtEuyIIBjXBGEQpnHj3BSyrwi9BFXKy5orQ4YcAzMZVC9FLokE1UfoyGtaeicCtRnV1ALAKzwdlTzOc-4PhLMIvd4SnNVc3LfIHWzJgY-Ym6NH4Y9uZqWuvnlAG6dy9Kkv-_g8Sccfx_JzhNpbv_z6MwhEgoTC1x2ubUA2zr6UKRcJz-FKIvRiM-yn4AFspV2slpJDGA2pOjzgaW0w149ubDBCfMuUNgKeAHx7BPwiEIE3fvDsv-88QHcDODEgkQ7RbnW1ss8hyKp0G1xrwtto791gdHbeDi72F50VJmY
link.rule.ids 230,315,730,783,787,888,12068,21400,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806,74073,74630
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELbYKgEviN-UjS1CsLd0SezYDi_TqDoVWCs0OtibZbt2KajpWFPEn89d4rUrmnjoky-pc7k738WfvyPkTeGNkdInMULMY0YzCy4FiVzuDPeQX_tc42nkwZD3z9nHi_wifHBbBFjldUysA_V4bvEb-WEqZCIK-CVHl79i7BqFu6uhhcYWaSFVFRRfrfe94eez9cnIou71mMKqGvOEikDbmFJ-iA2jq44sOqzDsF3Zlpn9WMXlFur4DwIl9QJ05ZsmF7dlof-CKW-sTicPyYOQVkbHjR08Indc-ZjcHYSN8ydk0PsdbCya-whPEU3LCDGwEDSgNp5ENXkvIp_eRTqysLShnJ5MF7PILKuonFf1hUicOTt6Ss5PeqNuPw6dFGLDU1lBtSkkT6yESWZcWwd1oIHwwph3jgubOWw7rTPhRD52PLfGaK5pzsc-zb2glj4j2-W8dC9IZLR0hdEJ9UwyShuCMEjThPV-DNVXm7wGRarLhitD1TUG5arWtpKFYgq03SYHqGeFTgRKszqcBYC_QDoqdVwUAjeEszZ5uyE4abi4b5Hb2ZADH7E3Rw_q97malb76iYA2kavh167q0rMkHX0ZqW9tsrfxwtePwSATZDk83e61Bajg7Au1Ns022V8N4xQQwFa6-XKhBKTRUKrDDZ435rK-dQZJosRrxYYhrQSQAHxzpJx-r4nAU8GLLKcv_z-pfXKvPxqcqtMPw0875H6NRqyhR7tku7pauleQVVVmL7jOX8WnHYA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdYK028IL7XbWwRgr2lTWLHTniZRmk1PlpNo4O9WbZrlw41HWuK-PO5S7x2RRMPffIldS5359_FP98R8iZ3WmeZi0KkmIeMJgZcCoBcajV3gK9dqvA08mDITy_Yp8v00vOfFp5WeRsTq0A9nhv8Rt6JRRaJHH5Rx3laxNmH_vH1rxA7SOFOq2-nsUWagnEaNUjzfW94dr4-JZlXfR9jWGFDHlHhSzjGlHeweXTZzvI2azNsXbalZ1erGN1Eff9B0qRagN5c3fDiPkT6L7HyzkrVf0weeYgZnNQ28YQ8sMVTsj3wm-jPyKD329tbMHcBniiaFgHyYSGAQJ48CapCvsiCeheowMAyh3JqMl3MAr0sg2JeVhdiEc3Z8XNy0e-Nuqeh76oQah5nJWSeIuORyWCSCVfGQk6oIdQw5qzlwiQWW1CrRFiRji1PjdaKK5rysYtTJ6ihL0ijmBd2hwRaZTbXKqKOZYzSulgYQDZhnBtDJtYir0GR8rqumyGrfINyWWlbZrlkErTdIkeoZ4kOBUozyp8LgL_A0lTyJM8Fbg4nLfJ2Q3BS1-W-R25vQw78xdwdPare52pW6uYnkttEKoffurJLz6N49HUkv7fIwcYLXz8GA1TIUni6_VsLkN7xF3Jtpi1yuBrGKSCZrbDz5UIKgNSQtsMNXtbmsr51AoAxw2vFhiGtBLAY-OZIMf1RFQWPBc-TlO7-f1KHZBu8Rn75OPy8Rx5WxMSKhbRPGuXN0r4CgFXqA-85fwFPgyGu
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evolution+of+statin+prescribing+1994%E2%80%932001%3A+a+case+of+agism+but+not+of+sexism%3F&rft.jtitle=Heart+%28British+Cardiac+Society%29&rft.au=DeWilde%2C+S&rft.au=Carey%2C+I+M&rft.au=Bremner%2C+S+A&rft.au=Richards%2C+N&rft.date=2003-04-01&rft.pub=BMJ+Publishing+Group+Ltd+and+British+Cardiovascular+Society&rft.issn=1355-6037&rft.eissn=1468-201X&rft.volume=89&rft.issue=4&rft.spage=417&rft_id=info:doi/10.1136%2Fheart.89.4.417&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_NVC_C3R01TST_W
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1355-6037&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1355-6037&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1355-6037&client=summon